Biomarkers of Renal Cancer to Improve Screening, Diagnosis, and Prognosis through Liquid Biopsies

What this Trial Is About

Researchers are studying renal cancer to identify a new molecular panel from liquid biopsies. This panel aims to distinguish renal cancer patients from healthy controls, differentiate malignant from benign kidney masses, assess the aggressiveness of renal cell carcinoma (RCC), and classify common RCC subtypes such as clear cell, papillary types 1 and 2, and chromophobe. The study combines molecular data with clinical information to improve screening, diagnosis, prognosis, and histological classification of renal cancer. The study includes two phases: a retrospective phase analyzing stored samples from patients with a first episode of renal mass and controls with urological functional diseases, and a prospective phase involving a multicenter trial. During the retrospective phase, various biological samples like plasma, urine, tumor tissue, and normal kidney tissue are analyzed using methods such as PCR, sequencing, and mass spectrometry. The prospective phase collects fresh whole blood, plasma, and urine samples from patients undergoing nephrectomy and controls, aiming to validate the biomarker panel in a larger group. Participants will provide biological samples before surgery, along with clinical data to build a comprehensive dataset. Researchers will analyze these samples to measure biomarkers related to screening, diagnosis, and prognosis of RCC. The study involves ongoing sample collection and data analysis to confirm the clinical usefulness of the biomarker panel for managing renal cancer. Participation includes providing informed consent and attending scheduled visits during the study period, which runs through June 2026.

Biomarkers of Renal Cancer